Apotex Health Corp. (TSX:APTX)
Canada · Delayed Price · Currency is CAD 33.25
-0.74 (-2.18%)
At close: Sep 18, 2026
Apotex Health Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
| 3,197 | 3,491 | 3,350 | 2,940 | |
Revenue Growth | - | 4.21% | 13.92% | - |
Cost of Revenue | 1,576 | 1,548 | 1,529 | 1,618 |
Gross Profit | 1,620 | 1,943 | 1,820 | 1,322 |
Selling, General & Admin | 729.96 | 635.01 | 571.42 | 502 |
Research & Development | 163.4 | 162.61 | 216.04 | 173.08 |
Other Operating Expenses | 93.25 | 75.12 | 34.79 | 18.57 |
Operating Expenses | 986.6 | 872.74 | 822.25 | 693.64 |
Operating Income | 633.83 | 1,070 | 997.98 | 628.71 |
Interest Expense | -263.34 | -255.64 | -232.92 | -174.44 |
Interest & Investment Income | 5.69 | 5.99 | 13.64 | 19.92 |
Currency Exchange Gain (Loss) | -46.88 | -5.8 | -25.03 | 7.65 |
Other Non Operating Income (Expenses) | -13.83 | -10.91 | 2.46 | -4.03 |
EBT Excluding Unusual Items | 315.47 | 803.62 | 756.14 | 477.82 |
Merger & Restructuring Charges | -95.11 | -110.32 | -79.74 | -437.98 |
Gain (Loss) on Sale of Assets | -1.23 | -1.23 | 2.28 | 4.39 |
Asset Writedown | -78.11 | -72.28 | -8.02 | - |
Legal Settlements | -72.52 | -69.88 | -154.19 | 20.14 |
Other Unusual Items | -21.11 | -30.04 | -205.85 | -219.93 |
Pretax Income | 47.38 | 519.87 | 310.63 | -155.56 |
Income Tax Expense | 74.65 | 146.09 | 158.93 | -8.64 |
Net Income | -27.27 | 373.78 | 151.7 | -146.92 |
Net Income to Common | -27.27 | 373.78 | 151.7 | -146.92 |
Net Income Growth | - | 146.39% | - | - |
Shares Outstanding (Basic) | 195 | 193 | 190 | 179 |
Shares Outstanding (Diluted) | 195 | 193 | 190 | 179 |
Shares Change | - | 1.77% | 6.11% | - |
EPS (Basic) | -0.14 | 1.94 | 0.80 | -0.82 |
EPS (Diluted) | -0.16 | 1.91 | 0.80 | -0.82 |
EPS Growth | - | 139.14% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 |
Free Cash Flow | 124.25 | 519.9 | 460.84 | 487.65 |
Free Cash Flow Per Share | 0.64 | 2.69 | 2.43 | 2.73 |
Dividend Per Share | - | - | 6.479 | 5.059 |
Dividend Growth | - | - | 28.05% | - |
Gross Margin | 50.69% | 55.65% | 54.34% | 44.97% |
Operating Margin | 19.83% | 30.65% | 29.79% | 21.38% |
Profit Margin | -0.85% | 10.71% | 4.53% | -5.00% |
Free Cash Flow Margin | 3.89% | 14.89% | 13.76% | 16.58% |
EBITDA | 761.63 | 1,189 | 1,104 | 748.62 |
EBITDA Margin | 23.83% | 34.06% | 32.95% | 25.46% |
D&A For EBITDA | 127.8 | 119.04 | 105.9 | 119.91 |
EBIT | 633.83 | 1,070 | 997.98 | 628.71 |
EBIT Margin | 19.83% | 30.65% | 29.79% | 21.38% |
Effective Tax Rate | 157.56% | 28.10% | 51.16% | - |